A recent study published in Nature Medicine examined the effectiveness of home-based transcranial direct current stimulation (tDCS) for major depressive disorder (MDD), offering new insight into the expanding field of neuromodulation treatments. The findings are encouraging — particularly in terms of accessibility and safety — but they also highlight important limitations of tDCS that reinforce why transcranial magnetic stimulation (TMS) continues to be the more effective, evidence-based option for patients with Depression, especially those with treatment-resistant illness.
Understanding the Study
The Nature Medicine study evaluated a 10-week, fully remote, randomized, double-blind, sham-controlled trial of home-based tDCS in adults with MDD. Participants self-administered treatment using a portable device while being remotely supervised via videoconference.
The primary outcome was improvement in depressive symptoms, measured using the Hamilton Depression Rating Scale (HDRS). Patients receiving active tDCS for depression showed a mean improvement of 9.41 points, compared to 7.14 points in the sham group — a statistically significant but modest difference of approximately 2 points. The FDA, in reviewing this data for its December 2024 approval of the Flow Neuroscience device, cited a moderate level of uncertainty of benefit, in part because a meaningful number of participants could identify whether they were receiving real or sham treatment.
The secondary outcomes were more compelling. By the end of the trial, 58.3% of participants receiving active tDCS for depression showed a clinical response, compared to 37.8% in the sham group. Remission rates were 44.9% in the active group versus 21.8% in the sham group — differences that are clinically meaningful and worth acknowledging honestly.
tDCS for depression was also found to be safe and well tolerated, with no serious adverse events related to the device and no differences in discontinuation rates between groups.
What Is tDCS for depression, and How Does It Work?
tDCS is a form of noninvasive brain stimulation that delivers a low-intensity electrical current through electrodes placed on the scalp. The goal is to modulate neuronal excitability, typically targeting the dorsolateral prefrontal cortex (DLPFC) — the same brain region implicated in Depression that TMS targets.
Unlike TMS, which directly induces neuronal firing through magnetic pulses, tDCS subtly shifts the likelihood that neurons will fire. This is a meaningful mechanical distinction, and one that helps explain the differences in clinical outcomes between the two treatments.
The portability of tDCS for depression is genuinely appealing from an accessibility standpoint. Because the device is relatively simple — a low-current electrical stimulator worn as a headset — it can be used at home, which removes a significant barrier for patients who cannot easily attend multiple weekly clinic appointments.
Where tDCS for Depression Falls Short
Despite its promise, the Nature Medicine study also reveals several limitations that matter for patients considering their treatment options.
The first is variability. Differences in skull thickness, brain anatomy, and electrode placement can significantly affect how much current reaches the target brain region. Even with remote supervision, standardized dosing produces inconsistent results across individuals in a way that in-clinic TMS, with precise electromagnetic targeting and consistent dosing parameters, does not.
The second — and most important for many patients — is the scope of the FDA approval. The agency approved tDCS as a first-line treatment for Depression, to be used on its own or alongside an antidepressant. It did not approve the device for patients who have already tried multiple treatments without adequate relief. This is a critical distinction. The majority of patients who come to Mid City TMS have treatment-resistant Depression — they have tried antidepressants, found them ineffective or intolerable, and are looking for a more powerful intervention. tDCS, as currently approved, is not indicated for this population.
The Nature Medicine study itself acknowledged this, noting that treatment-resistant Depression is negatively correlated with clinical response to tDCS for depression.
Why TMS Remains the Superior Option for Treatment-Resistant Depression
TMS has been FDA-cleared for treatment-resistant Depression since 2008, supported by decades of randomized controlled trials and real-world clinical data. At Mid City TMS, Dr. Bruno has achieved response rates of over 75% and full remission in more than one in three patients — outcomes that reflect both the strength of the treatment and the importance of experienced clinical oversight.
Where tDCS uses a weak electrical current to nudge neuronal activity, TMS uses focused magnetic pulses to directly stimulate specific brain circuits. This produces stronger, more durable changes in brain function — and more predictable outcomes across patients. TMS also benefits from precise neuro-navigation and standardized protocols that home-based administration simply cannot replicate.
For patients with moderate or mild Depression who have not yet tried other treatments, tDCS may represent a viable and accessible option. That is a legitimate role for the technology, and the Nature Medicine findings support it. But for patients with moderate-to-severe, treatment-resistant, or functionally impairing Depression — the patients most likely to be seeking care at a specialized TMS practice — the evidence overwhelmingly supports TMS as the more effective choice.
A Broader Shift Worth Watching
The FDA approval of tDCS is part of a larger movement in psychiatry to develop treatments that go beyond antidepressant medications. That is a direction worth supporting. As awareness grows that Depression involves dysregulation of brain circuits — not simply a chemical imbalance — noninvasive brain stimulation treatments like TMS and tDCS are gaining the attention they deserve.
At Mid City TMS, we have been at the forefront of this shift for years. We stay current with the clinical literature, including studies like this one, because our patients deserve care that reflects the best available evidence. If you have questions about whether TMS is the right option for you, we’re happy to consult with you.
Contact us today to learn more.
Sources
- Fu, C. et al. (2025). Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial. Nature Medicine, 31, 87–95. https://doi.org/10.1038/s41591-024-03305-y
- Gross, R.E. (2026, April 28). Could At-Home Brain Stimulation Reduce Psychiatry’s Reliance on S.S.R.I.s? The New York Times. https://www.nytimes.com/2026/04/28/health/depression-at-home-brain-stimulation-fda.html?
- Bikson, Marom, et al. “US FDA Approves Home-Delivered tDCS for Treating Depression.” Brain Stimulation, vol. 19, no. 1, 2026, p. 103021, https://doi.org/10.1016/j.brs.2025.103021.